Evidence map›Paper›PMID 21510986›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2011

Preferential cellular uptake of amphiphilic macromolecule-lipid complexes with enhanced stability and biocompatibility.

Alexander M Harmon, Melissa H Lash, Sarah M Sparks, Kathryn E Uhrich

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Cationic amphiphilic macromolecule (CAM)-lipid complexes for efficient siRNA gene silencing.Journal of controlled release : official journal of the Controlled Release Society · 2014
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Alexander M HarmonDepartment of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ 08854, USA.
Melissa H Lash
Sarah M Sparks
Kathryn E Uhrich
Rutgers, The State University of New Jersey · US

Funding

Synthetic Counter-ligands for Inhibition of AtherosclerosisR01HL107913 · NHLBI · RUTGERS, THE STATE UNIV OF N.J. · PI MOGHE, PRABHAS V, UHRICH, KATHRYN ELIZABETH · 2011 to 2014
$2.3M
NHLBI NIH HHS R01 HL107913
6 · The paper itself

Abstract

Amphiphilic macromolecules (AM) were electrostatically complexed with a 1:1 ratio of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) to form AM-lipid complexes with drug delivery applications. The complexes exist as AM-coated liposomes and their drug delivery properties can be tuned by altering the AM-lipid weight ratio. The complexation and tuning are achieved in a simple, efficient, and scalable manner. The gradual increase in lipid ratios concurrently increased the zeta potential of the complexes, which directly correlates to increased cell uptake of the complexes in vitro with preferential uptake noted in BT-20 carcinoma cells versus normal fibroblasts. Increasing AM content increased complex steric stability in the presence of serum proteins and reduced the inherent cytotoxicity towards fibroblasts in vitro. AM-lipid complexes solubilized paclitaxel and showed drug-mediated, dose-dependent cytotoxicity towards target BT-20 cells in vitro. AM-lipid complexes make good candidates as drug delivery systems due to their tunable zeta potential, steric stability, inherently low cytotoxicity, and ability to load and deliver insoluble chemotherapeutic agents. Significantly, their preferential uptake in a carcinoma cell line over normal cells in vitro demonstrates a unique, passive targeting approach to delivery anti-cancer therapeutics.

Indexed as

Antineoplastic Agents, PhytogenicBiocompatible MaterialsCell Line, TumorCell SurvivalDrug CarriersDrug StabilityFatty Acids, MonounsaturatedFibroblastsFluorescein-5-isothiocyanateHumansLipidsMacromolecular SubstancesPaclitaxelPhosphatidylethanolaminesQuaternary Ammonium CompoundsSurface-Active Agents1,2-dioleoyl-glycero-3-phosphatidyl ethanolamine1,2-dioleoyloxy-3-(trimethylammonium)propaneAntineoplastic Agents, PhytogenicBiocompatible MaterialsDrug CarriersFatty Acids, MonounsaturatedFluorescein-5-isothiocyanateLipidsMacromolecular SubstancesPaclitaxelPhosphatidylethanolaminesQuaternary Ammonium CompoundsSurface-Active Agents

Identifiers

PMID21510986
PMCPMC3564574
OpenAlexW2050399778

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.